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Abstract: Small molecule-drug conjugates (SMDCs) represent an alternative to conventional anti-tumor
chemotherapeutic agents, with the potential to improve the therapeutic window of cytotoxic payloads
through active delivery at the site of the disease. In this article we describe novel combination therapies
consisting of anti-Carbonic Anhydrase IX SMDCs combined with different immunomodulatory products.
The therapeutic effect of the SMDCs was potentiated by combination with PD-1 blockade and with
tumor-homing antibody-cytokine fusions in mouse models of renal cell carcinoma and colorectal cancer.
The combination with L19-IL12, a fusion protein specific to the alternatively-spliced EDB domain of
fibronectin containing the murine interleukin-12 moiety, was active also against large established tumors.
Analysis of the microscopic structures of healthy organs performed three months after tumor eradication
confirmed absence of pathological abnormalities in the healthy kidney, liver, lung, stomach and intestine.
Our findings may be of clinical significance as they provide motivation for the development of combinations
based on small molecule-drug conjugates and immunotherapy for the treatment of renal cell carcinoma
and of hypoxic tumors.
DOI: https://doi.org/10.1158/1535-7163.mct-20-0361





Millul, Jacopo; Krudewig, Christiane; Zana, Aureliano; Plaza, Sheila Dakhel; Puca, Emanuele; Villa,
Alessandra; Neri, Dario; Cazzamalli, Samuele (2021). Immunotherapy with immunocytokines and PD-1
blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase
IX. Molecular Cancer Therapeutics, 20(3):512-522.
DOI: https://doi.org/10.1158/1535-7163.mct-20-0361
1 
Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer 
















 & Samuele Cazzamalli
a
*
a) Philochem AG, Libernstrasse 3, CH-8112 Otelfingen (Switzerland)
b) Laboratory for Animal Model Pathology, Universität Zürich, Winterthurerstrasse 268,
CH-8057 Zurich (Switzerland) 
c) Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Tech-
nology (ETH Zürich), Vladimir-Prelog-Weg 4, CH-8093 Zurich (Switzerland) 
*) Corresponding author 
phone: +41 43 544 88 19 
fax: +41 43 544 88 09 
samuele.cazzamalli@philogen.com 
Running Title:  
Immunotherapy in combination with anti-CAIX SMDCs 
Keywords: 
Tumor Targeting, Small Molecule-Drug Conjugates, Immunotherapy, Carbonic Anhy-
drase IX, Therapy Studies 
on January 19, 2021. © 2020 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 











D.N. acknowledges funding from ETH Zurich. This project has received funding from 
the Swiss National Science Foundation (Grant Nr. 310030_182003/1) and the Europe-
an Research Council (ERC) under the European Union’s Horizon 2020 research and 
innovation program (grant agreement 670603). 
 
Disclosure of Potential Conflict of Interest:  
D.N. is a co-founder and shareholder of Philogen (www.philogen.com), a Swiss-Italian 
Biotech company that operates in the field of ligand-based pharmacodelivery. J.M., 
A.Z., S.D.P., E.P., A.V. and S.C. are employees of Philochem AG, daughter company 
of Philogen acting as discovery unit of the group. 
 
Submitted as Research Article to Molecular Cancer Therapeutics 
  
on January 19, 2021. © 2020 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 











Small molecule-drug conjugates (SMDCs) represent an alternative to conventional anti-
tumor chemotherapeutic agents, with the potential to improve the therapeutic window of 
cytotoxic payloads through active delivery at the site of the disease. In this article we de-
scribe novel combination therapies consisting of anti-Carbonic Anhydrase IX SMDCs 
combined with different immunomodulatory products. The therapeutic effect of the 
SMDCs was potentiated by combination with PD-1 blockade and with tumor-homing an-
tibody-cytokine fusions in mouse models of renal cell carcinoma and colorectal cancer. 
The combination with L19-IL12, a fusion protein specific to the alternatively-spliced 
EDB domain of fibronectin containing the murine interleukin-12 moiety, was active also 
against large established tumors. Analysis of the microscopic structures of healthy organs 
performed three months after tumor eradication confirmed absence of pathological ab-
normalities in the healthy kidney, liver, lung, stomach and intestine. Our findings may be 
of clinical significance as they provide motivation for the development of combinations 
based on small molecule-drug conjugates and immunotherapy for the treatment of renal 
cell carcinoma and of hypoxic tumors. 
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The vast majority of cancer patients receive chemotherapy as part of combination treat-
ments [1]. The clinical efficacy of conventional chemotherapeutic drugs is often limited 
by their unfavorable biodistribution profile [2]. The use of antibodies, specific to certain 
tumor-associated antigens and serving as drug delivery vehicles, may improve the thera-
peutic window of potent cytotoxic agents [3–5]. This approach has led to the marketing 
authorization of eight antibody-drug conjugates (ADCs; Mylotarg™, Kadcyla™, Adce-
tris™, Besponsa™, Polivy™, Padcev™, Enhertu™ and Trodelvy™) [4,6–9]. While the 
clinical benefit of ADCs has become evident, the therapeutic window of these biophar-
maceuticals is narrower than what had initially been estimated on the basis of preclinical 
studies [10,11]. The toxicity profile of ADC products often involves organs which do not 
express the target antigen and may be substantial when approaching the maximal tolerat-
ed dose [12,13]. The implementation of site-specific ADCs has been recently described 
as a strategy to improve their therapeutic index [14], but a clear proof of their clinical 
benefit over old generation products still lacks. 
 
ADC products often extravasate slowly over the blood vessel walls and may exhibit a 
heterogeneous distribution within solid tumor masses [15,16]. Small molecule-based tar-
geting agents may represent an alternative to antibodies. Excellent biodistribution profiles 
in mouse and man have been reported for small organic ligands specific to folate receptor 
[17], prostate-specific membrane antigen [18], fibroblast activation protein [19,20] and 
carbonic anhydrase IX [21]. The chemical conjugation of a small organic tumor targeting 
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moiety to a cytotoxic drug leads to the generation of a novel class of therapeutic com-
pounds named small molecule-drug conjugates (SMDCs) [22–24] which may represent 
an alternative to ADCs. Small ligands extravasate within seconds and may reach tumor 
cells far away from blood vessels [22]. In a recent direct comparison of an ADC and a 
SMDC directed against carbonic anhydrase IX, the small drug conjugate exhibited a bet-
ter and more efficient tumor uptake, but both conjugates were efficacious in controlling 
tumor growth [25].  
 
Carbonic anhydrase IX (CAIX) is a transmembrane homodimeric protein and a validated 
target for drug delivery applications [26]. CAIX is over-expressed in the majority of clear 
cell renal cell carcinomas (ccRCCs) and in hypoxic tumors, while its expression in nor-
mal tissues is mainly confined to certain structures of the gastrointestinal tract [27]. Both 
antibodies and small molecules have been successfully used to target CAIX-positive tu-
mors in vivo [28–30]. Acetazolamide (AAZ), a small organic nanomolar binder of CAIX, 
represents a “portable” moiety for the active delivery of radionuclides, fluorophores and 
cytotoxic drugs [21,30–32]. 
 
We have recently described the generation of new anti-tumor SMDC products based on 
acetazolamide (AAZ) and on its affinity-matured derivative, called acetazolamide-plus 
(AAZ
+
) [33]. In this study, the two compounds were conjugated through the cleavable 
valine-citrulline linker (Val-Cit) to the potent tubulin inhibitor monomethyl auristatin E 
(MMAE), also used in Adcetris® [34,35].  
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We observed a potentiation of anti-CAIX SMDC products using antibody-interleukin-2 
and with antibody-interleukin-12 fusion proteins, that target the alternatively-spliced 
EDB domain of fibronectin [36]. Moreover, we studied the combination of SMDCs with 
a PD-1 immune checkpoint inhibitor [37]. All combinations were found to be safe over a 
prolonged period of time, as demonstrated by histopathological analysis performed on 
organs derived from cured animals. Our results provide a rationale for the clinical devel-
opment of combination treatments based on the acetazolamide SMDC products, ideally in 
combination with tumor homing antibody-cytokine fusions or with anti-PD-1 antibodies. 
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Materials and Methods 
Detailed synthetic procedures and characterization of the presented compounds are de-
scribed in the Supplementary Information. 
 
Preparation of SMDCs 
AAZ-ValCit-MMAE was prepared following well-established synthetic procedures [31]. 
Briefly, commercially available MC-ValCit-PAB-MMAE (1 eq.) was reacted with com-
pound 1 (4 eq. dissolved in 100 µl of DMF) in freshly degassed phosphate buffered saline 
(PBS; 50 mM phosphate, 100 mM NaCl, pH 7.4; 900 µl). The reaction was stirred at 
room temperature until completion (monitored by LC/MS). The crude was directly puri-
fied through RP-HPLC and solvents were removed by lyophilization. The identity and 
purity (98 %) of the final product was assessed by LC/MS.  
AAZ
+
-ValCit-MMAE was prepared following well-established synthetic procedures [31]. 
Briefly, commercially available MC-ValCit-PAB-MMAE (1 eq.) was reacted with com-
pound 2 (4 eq. dissolved in 100 µl of DMF) in freshly degassed phosphate buffered saline 
(PBS; 50 mM phosphate, 100 mM NaCl, pH 7.4; 900 µl). The reaction was stirred at 
room temperature until completion (monitored by LC/MS). The crude was directly puri-
fied through RP-HPLC and solvents were removed by lyophilization. The identity and 
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Preparation of L19-IL12 
The immunocytokine L19-IL12 was cloned as previously described [36]. Briefly, the fu-
sion protein was produced in CHO-S mammalian cells and purified from the cell culture 
medium by affinity chromatography using a Protein A (Sino Biological) affinity column, 
as described previously [36]. After dialysis into PBS pH 7.4, the quality of the protein 
was assessed by size-exclusion chromatography and by SDS-PAGE [Supplementary 
Figure 1]. Binding to the cognate EDB antigen was assessed by Surface Plasmon Res-
onance [Supplementary Figure 1] following previously described procedures [36]. 
 
Cell cultures 
The human renal cell carcinoma cell line SKRC-52 was kindly provided by Professor E. 
Oosterwijk (Radbound University Nijmegen Medical Centre, Nijmegen, The Nether-
lands). SKRC-52 cells were cultured in RPMI medium (Invitrogen), supplemented with 
fetal calf serum (10%, FCS, Invitrogen) and Antibiotic-Antimycotic (1%, AA, Invitro-
gen) at 37°C, 5% CO2. Cells at 90-100% confluence were detached using Trypsin-EDTA 
0.05% (Invitrogen) and re-seeded at a dilution of 1:6. 
The murine colorectal carcinoma CT26-3E10 transfected cell [31] were cultured in RPMI 
medium (Invitrogen), supplemented with fetal calf serum (10%, FCS, Invitrogen) and 
Antibiotic-Antimycotic (1%, AA, Invitrogen) at 37°C, 5% CO2. Cells at 90-100% con-
fluence were detached using Trypsin-EDTA 0.05% (Invitrogen) and re-seeded at a dilu-
tion of 1:6. 
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All animal experiments were conducted in accordance with Swiss animal welfare laws 
and regulations under the license number ZH004/18 granted by the Veterinäramt des 
Kantons Zürich. 
 
Implantation of subcutaneous tumors 
SKRC-52 cells were grown to 80-100% confluence and detached with Trypsin-EDTA 
0.05% (Invitrogen). Cells were washed once with Hank’s Balanced Salt Solution (HBSS, 
Thermo Fisher Scientific, pH 7.4), counted and re-suspended in HBSS. Aliquots of 5-10 
× 10
6
 cells were resuspended in 150 µl of HBSS and injected subcutaneously in the right 
flank of female athymic BALB/c nu/nu mice (8-10 weeks of age, Janvier). 
CT26-3E10 cells were grown to 80-100% confluence and detached with Trypsin-EDTA 
0.05% (Invitrogen). Cells were washed once with Hank’s Balanced Salt Solution (HBSS, 
Thermo Fisher Scientific, pH 7.4), counted and re-suspended in HBSS. Aliquots of 6 × 
10
6
 cells were resuspended in 150 µl of HBSS and injected subcutaneously in the right 
flank of female athymic BALB/c nu/nu mice (8-10 weeks of age, Janvier). 
 
Quantification of MMAE in SKRC-52 tumors 
SKRC-52 tumor cells were implanted into female BALB/c athymic nu/nu mice and al-
lowed to grow to an average volume of 100 mm
3
. AAZ-ValCit-MMAE was injected 
through tail vein injection (250 nmol/Kg) and animals were euthanized at different time 
points (i.e., 10 min, 1h, 3h, 6h and 24h after the administration). The tumors were col-
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lected, frozen and stored at -80°C prior to sample preparation and LC/MS quantification 
of MMAE. Blood was collected and incubated for 20 min in Microtainer tubes containing 
lithium heparin (BD Microtainer Tube). Plasma was obtained by centrifugation for 15 
min at 3’000 rpm using a refrigerated centrifuge and stored at -80°C prior to sample 
preparation and LC/MS quantification of MMAE. The detailed protocol for processing 
the samples is described in the Supplementary information. 
 
Dose escalation study with L19-IL12 
A dose escalation study with L19-IL12 was performed in athymic BALB/c nu/nu mice 
(8-10 weeks of age, Janvier). Four different doses of the immunocytokine were tested 
following the schedule reported in the Supplementary Information (three intravenous 
injections per animal at 0.6, 0.8, 1 or 1.2 mg/kg). Animals were weighed daily to assess 
acute toxicity of the immunocytokine at the different doses. 
 
Therapy experiments 
SKRC-52 or CT26-3E10 tumor cells were implanted into female BALB/c nu/nu mice and 




. Mice were randomly as-
signed into therapy groups of 3, 4 or 5 animals. Intravenous injections of AAZ-ValCit-
MMAE (250 nmol/kg), AAZ
+
-ValCit-MMAE (250 nmol/kg), L19-IL2 (2.5 mg/kg), anti-
PD-1 (10 mg/kg), L19-IL12 (1.2 mg/kg) or vehicle were performed with the schedules 
indicated in the text and in Fig. 2, 3 and 4. Compounds 1 and 2 were injected as sterile 
PBS solution with 1% of DMSO. L19-IL12 and anti-PD-1 were injected as sterile PBS 
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solution. L19-IL2 was injected in sterile formulation buffer (Philogen). Tumors were 
measured with an electronic caliper and animals were weighted daily. Tumor volume 
(mm
3
) was calculated with the formula (long side, mm) x (short side, mm) x (short side, 
mm) x 0.5. Animals were sacrificed when one or more termination criteria indicated by 
the experimental license were reached (e.g. weight loss > 15%). Prism 6 software 
(GraphPad Software) was used for data analysis (regular two-way ANOVA followed by 
Bonferroni test). 
 
Evaluation of chronic toxicity by plasma analysis and ex vivo histology 
SKRC-52 bearing mice treated with vehicle, SMDC products and immunocytokines as 
single agents or their combinations (n = 3 per group) were sacrificed 90 days after treat-
ment. The plasma was collected for each mouse and analyzed to detect the level of creat-
inine and urea. A complete gross post mortem examination had been performed on each 
mouse, gross abnormalities recorded and all tissues collected in 10% buffered formalin 
for histological analysis. The tissue was trimmed, dehydrated, and embedded in paraffin 
wax. Sections of 3-4 μm thickness were prepared, mounted on glass slides, deparaffinized 
in xylene, and rehydrated through graded alcohols, before staining with hematoxylin and 
eosin (HE) for the histological examination. Samples containing bone (bone marrow) 
were demineralized after fixation with EDTA for 48 hours prior to further processing as 
described above. The microscopic morphology of different organs (kidney, liver, lung, 
stomach, bone marrow and spleen) was blindly analyzed by a board-certified pathologist. 
Separately and afterwards they were compared to corresponding control samples collect-
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ed from a non-treated animal to highlight structural changes deriving from the different 
treatments.  
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Production and characterization of SMDCs and immunocytokines 
The structure of AAZ-ValCit-MMAE and AAZ
+
-ValCit-MMAE are shown in Figure 





CAIX targeting moiety [31], were prepared by solid phase peptide synthesis following a 
conventional Fmoc-strategy and purified by reverse phase HPLC. Compounds 1 and 2 
were coupled in solution to the linker-payload module used for Adcetris™, composed by 
the cleavable linker Valine-Citrulline, a self-immolative para-aminobenzyl carbamate 
moiety and the potent anti-tubulin poison monomethyl auristatin E (MMAE). The result-
ing AAZ-ValCit-MMAE and AAZ
+
-ValCit-MMAE products were used for therapy stud-
ies in tumor-bearing mice. 
The immunocytokine L19-IL12, recently described by our group, is a fusion protein con-
sisting of the L19 antibody in tandem diabody format fused to a single-chain of the mu-
rine IL-12 by the (GGGGS)3 15-amino-acid linker [36] [Figure 1B]. We have also previ-
ously reported the fusion of the L19 antibody with interleukin-2 [31] [Figure 1C]. Struc-
tural and analytical information for all products is reported in the Supplementary In-
formation and Supplementary Figure 1. 
 
 
Quantification study of MMAE in SKRC-52 tumor 
We quantified the amount of the MMAE cytotoxic payload released in tumors and in 
plasma after injection of a single dose of AAZ-ValCit-MMAE pro-drug (250 nmol/Kg) in 
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SKRC-52 tumor bearing mice [Figure 1D]. A high and stable accumulation of free 
MMAE was observed in tumor samples. The highest concentration was obtained in tumor 
samples collected 3 hours after the intravenous injection, with values corresponding to 
270 pmol/gram of tissue (i.e., to 5.4% of the injected dose per gram). Free MMAE levels 
in circulation quickly went down to values lower that 1% of the injected dose per mL of 
plasma already 1 hour after injection of the AAZ-ValCit-MMAE prodrug. 
 
Therapy experiment of combination of SMDCs and L19-IL2 in SKRC-52 renal cell car-
cinoma model  
We had previously reported that L19-IL2 potentiates the anti-cancer activity of AAZ
+
-
ValCit-MMAE in two mouse models of cancer [31] and that the AAZ
+
 moiety targets 
tumors more efficiently than AAZ [38]. Here, we performed a comparison of AAZ-
ValCit-MMAE and AAZ
+
-ValCit-MMAE in combination with L19-IL2, in order to study 
the activity and tolerability of the two drugs in BALB/c athymic nude mice bearing sub-
cutaneously-grafted SKRC-52 tumors. 
AAZ-ValCit-MMAE and AAZ
+
-ValCit-MMAE were administered at 250 nmol/Kg, a 
dose that was previously identified to be compatible with selective accumulation of AAZ 
derivatives in tumors and which appeared to be safe and effective in the SKRC-52 renal 
cell carcinoma model [21,25,31]. The antibody-fusion protein L19-IL2 was administered 
at 2.5 mg/Kg, previously identified as a efficacious and well tolerated dose [31]. Therapy 





the simultaneous administration of SMDC and L19-IL2 with a modified schedule, featur-
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ing a 24-hour delay between the two injections [Figure 2A and 2C], as it has previously 
been suggested that immunotherapy may benefit from the damage caused to the tumor by 
cytotoxic agents [39]. A potent in vivo anti-cancer activity of both SMDCs in combina-
tion with L19-IL2 was observed in both schedules [Figure 2A and 2C]. AAZ
+
-ValCit-
MMAE was more active in this study, leading to 4/4 cures in combination with L19-IL2 
in the sequential administration schedule and 2/4 cures upon simultaneous administration 
[Figure 2C]. All treatments were well tolerated at the administered doses [Figure 2B 
and 2D]. 
 
In a second therapy experiment, we tested the anti-cancer activity of the combination 
AAZ
+
-ValCit-MMAE and L19-IL2 on larger established SKRC-52 tumors starting at an 
average volume of 200 mm
3
. The administration of AAZ
+
-ValCit-MMAE as single 
agents resulted in a partial tumor growth retardation [Figure 2E]. Interestingly, only the 
combination of AAZ
+
-ValCit-MMAE and L19-IL12 induced potent tumor regression in 
this setting (i.e., 3 of the 4 animals treated were cured). The combination treatment was 
well tolerated and no sign of acute toxicity was observed [Figure 2F]. 
 
Therapy experiment of combination of SMDCs and anti-PD-1 in CT26-3E10 colorectal 
cell carcinoma model 
The anti-cancer activity of AAZ-ValCit-MMAE, of AAZ
+
-ValCit-MMAE, of anti-PD-1 
and of their combination was assessed in fully immunocompetent BALB/c mice bearing 
subcutaneously CT26-3E10 colorectal cell carcinoma. AAZ-ValCit-MMAE and AAZ
+
-
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ValCit-MMAE were administered at 250 nmol/Kg, as previously mentioned. The anti-
PD-1 antibody was administered at the dose of 10 mg/Kg, as previously described [37]. 




The compounds were administered the same day, with a 6 hours interval between the two 
injections, starting with the SMDC [Figure 3A]. A potent anti-cancer activity of AAZ-
ValCit-MMAE, AAZ
+
-ValCit-MMAE and anti-PD-1 were observed in vivo when the 
products were given as combination, while the single treatment with anti-PD-1 was inef-
fective [Figure 3A]. All treatments were well tolerated at the doses administered [Figure 
3B]. 
 
Therapy experiments of combination of SMDC and L19-IL12 in SKRC-52 renal cell car-
cinoma model 
The anti-cancer activity of AAZ
+
-ValCit-MMAE, of L19-IL12 and of their combination 
was assessed in BALB/c athymic nude mice bearing subcutaneously-grafted SKRC-52 
renal cell carcinoma. AAZ
+
-ValCit-MMAE was administered at 250 nmol/Kg. The anti-
body-fusion protein L19-IL12 was administered at the dose of 1.2 mg/Kg. This dose was 
considered to be safe based on a preliminary dose escalation experiment in nude mice 
[Supplementary Information]. Therapy started when the average volume of established 




The two compounds were administered according to the sched-
ule described in Figure 4A. A potent anti-cancer activity for AAZ
+
-ValCit-MMAE and 
for L19-IL12 was observed in vivo when products were given as monotherapy. Moreover, 
all animals treated with the combination of the two products experienced a complete and 
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durable tumor eradication [Figure 4A]. AAZ
+
-ValCit-MMAE, L19-IL12 and their com-
bination treatment were well tolerated at the administered doses [Figure 4B]. Cured ani-
mals were kept alive and tumor-free for 90 days after the administration of the first dose 
of SMDC [Figure 4A]. 
In a second therapy experiment, we tested the anti-cancer activity of the combination 
AAZ
+
-ValCit-MMAE and L19-IL12 on larger established SKRC-52 tumors (average
volume of 200 mm
3
) implanted in BALB/c nude mice. The administration of AAZ
+
-
ValCit-MMAE and L19-IL12 as single agents resulted in a partial tumor growth retarda-
tion, compared to saline-treated animals used as controls [Figure 4C]. Interestingly, only 
the combination of AAZ
+
-ValCit-MMAE and L19-IL12 induced tumor regression in this
setting. All treatments were well tolerated and no sign of acute toxicity was observed 
[Figure 4D]. Mice in the combination group received a second cycle of injections (i.e. 
AAZ
+
-ValCit-MMAE and L19-IL12) on therapy day 52. During this second round of
treatments, an acute and reversible body weight loss was observed as sign of toxicity 
[Figure 4D]. Mice treated with the combination were kept alive for more than 60 days 
[Figure 4C]. 
Analysis of chronic toxicity of combination treatment of SMDCs with L19-IL2 
Gross examination of mice revealed a slightly to moderately enlarged spleen of all ani-
mals treated with L19-IL2 alone or in combination with SMDCs compared to the control 
group. Histologically, none of the treatments caused cellular infiltration and/or connec-
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tive tissue (fibrosis) in liver and kidney of the treated animal in comparison with speci-
mens from control animals. No signs of toxicity were found in other healthy organs, in-
cluding lung and stomach that are known to be exposed to higher concentration of AAZ-
based derivatives [Figure 5A] [30]. Urea and creatinine plasma levels measured three 
months after treatment with SMDCs, L19-IL2 and combinations (blood chemistry for 
kidney chronic toxicity) revealed no significant differences between treatment groups and 
compared to the control group [Figure 5B and 5C]. 
Analysis of chronic toxicity of combination treatment of SMDCs with L19-IL12 
Gross examination of mice revealed a moderately enlarged spleen in all animals treated 
with L19-IL12 alone or in combination with AAZ
+
-ValCit-MMAE compared to the con-
trol group. In the liver, both treatment groups exhibited a mild [40] periportal infiltrate of 
mononuclear cells [Figure 6], rarely associated with increased connective tissue. Both 
changes were not noted in the control animal and did not differ significantly in between 
the groups. The histopathological examination of kidney, lung and stomach did not show 
signs of inflammation and /or fibrosis [Figure 6]. In the spleen, a marked increase in ex-
tramedullary hematopoiesis in the red pulp correlated macroscopically with an enlarged 
spleen. The bone marrow of both treatment groups revealed a high cellularity with all 
three cell lines: erythropoiesis, myelopoiesis and thrombocytopoiesis were present with 
maturation in all three lines and did not seem to be altered compared to the control ani-
mal. [Supplementary information]. 
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Discussion 
We have recently demonstrated that the anti-cancer activity of AAZ
+
-ValCit-MMAE, a
small molecule-drug conjugate targeting carbonic anhydrase IX, is potently enhanced by 
the combination with targeted interleukin-2 [31]. In this article we have extended our 
previous findings, describing the in vivo anti-cancer activity and safety profile of novel 
therapies consisting of SMDC products targeting carbonic anhydrase IX combined with 
PD-1 blockade and with the antibody-cytokine fusions L19-IL2 and L19-IL12. Combina-
tion with all immunomodulatory drugs tested enhanced the therapeutic activity of small 
molecule-drug conjugates. The result of a systematic histopathological evaluation in 
treated mice shows that curative doses of SMDCs in combination with L19-IL2 and with 
L19-IL12 do not cause chronic toxicity in kidney and other healthy organs. 
The clinical efficacy of targeted cytotoxics strictly depends on the amount of payload that 
can be delivered to the tumor cells, compatibly with a safe administration to the patients. 
While being designed to specifically deliver their toxic payload to tumors, both ADCs 
and SMDCs are found at significantly high concentrations in non-target organs [41]. An-
tibody-drug conjugates are slowly cleared by the liver. Common clinical side effects of 
ADCs include liver damage, bone marrow toxicity and hemorrhage [11]. Small molecule-
drug conjugates are rapidly cleared by the kidney, with very short plasma half-lives and 
time of exposure in other healthy organs. In this article, we have shown how the fast 
clearance of Small Molecule-Drug Conjugates does not impair their therapeutic efficacy. 
Bioanalysis of tumor samples clearly shows that high and stable concentration of cytotox-
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ic drugs can be delivered by acetazolamide conjugates over a time window of 24 hours 
after intravenous administration. Our data are consistent with recently published literature 
data on clearance of Peptide-Drug Conjugates and in vivo delivery of MMAE to tumors 
[42]. The toxicity profile of SMDCs has not been sufficiently investigated, with only few 
preclinical [42,43] and clinical [44] examples available at present. We have demonstrated 
that anti-CAIX SMDC products are safe when administered at curative doses, with no 
signs of chronic damage in non-target healthy organs and in those healthy structures 
known to express CAIX [27,31]. These findings are in strong contrast with what has been 
reported for small molecule-radio conjugates, for which administration of therapeutic 
doses typically results in significant kidney toxicity [45]. Our results suggest that the de-
livery of cytotoxic drugs damaging cells in rapid proliferation may be advantageous over 
the use of therapeutic radionuclide payloads that damage indistinctively all type of cells 
[46]. 
 
Immunocytokines and checkpoint inhibitors have previously been found to potently en-
hance the anti-cancer activity of untargeted chemotherapy [39,47] and of antibody-drug 
conjugates [48]. When given as combination, the administration of immunotherapy and 
of cytotoxic drugs can be harmonized to maximize therapeutic potential and minimize 
systemic toxicities. We could show that the different tumor residence time of AAZ-
ValCit-MMAE and AAZ
+
-ValCit-MMAE has an impact on the therapeutic outcome of 
the combination treatment. Moreover, we found that SMDC products based on AAZ ad-
ministered before immunotherapy were more efficacious than immunotherapy first fol-
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lowed by SMDCs. This findings are in keep with what previously observed in preclinical 
experiments performed with combinations of conventional chemotherapeutic agents and 
immunocytokines [39]. We suggest that the initial damage induced by targeted cytotoxics 
can render the tumor microenvironment more susceptible to the action of immunothera-
py, as cytotoxic agents increase the expression of stress proteins such as Mic-A [39,49] 
and cause immunogenic cell death [50]. 
We have previously demonstrated that the combination treatment based on AAZ
+
-ValCit-
MMAE and L19-IL2 is able to promote the NK infiltration in large tumors [31]. Moreo-
ver, we have already shown that L19-IL12 is able to boost NK cell tumor infiltration in 
monotherapy [36]. The therapy experiments performed in large tumors presented in this 
paper suggest that the immunosuppressive environment represent the major driver of the 
reduction of anti-tumor activity of immunocytokine products (i.e., NK cells are present in 
the tumor, but they are “immunosuppressed”) and that the combination with cytotoxic 
insults leads to potent anticancer activity in large lesions. 
Our results provide a rationale for the clinical development of anti-CAIX small molecule-
drug conjugates in combination with immunocytokines and PD-1 inhibitors. Small mole-
cule-drug conjugates may represent a valuable alternative to antibody-drug conjugates, 
with clear advantages in terms of tumor targeting performance [25] and ease of manufac-
ture [10]. 
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Figure Captions 
Figure 1: Small molecule-drug conjugates targeting CAIX, antibody-fusion proteins 
targeting EDB domain of Fibronectin and bioanalysis of MMAE released in vivo by 
AAZ-ValCit-MMAE. (A) Chemical structures of AAZ-ValCit-MMAE, AAZ
+
-ValCit-
MMAE and of corresponding payload and linker-payload modules. (B) Schematic struc-
ture of L19-IL12 (C) and of L19-IL2. (D) Quantification of free MMAE in SKRC-52 
tumors and plasma at different time points after intravenous administration of AAZ-
ValCit-MMAE in tumor bearing mice at a dose of 250 nmol/Kg. SC = succinimido-
caproyl; PAB = para-amino-benzyl. 
Figure 2: In vivo efficacy of AAZ-ValCit-MMAE and AAZ
+
-ValCit-MMAE in com-
bination with L19-IL2 in BALB/c immunodeficient nu/nu mice bearing established 
subcutaneous SKRC-52 renal cell carcinoma. (A) Therapeutic activity of the different 
treatments as assessed by measurement of tumor volume (mm
3
) during therapy experi-
ment. Data points represent mean tumor volume ± SEM (n = 4 per group). The two 
treatments were administered intravenously as bolus injections with a 24-hour gap, start-
ing from the SMDCs. (B) Tolerability of the different treatments as assessed by the eval-
uation of changes (%) in body weight during the experiment when the two treatments 
were given with a 24 hours gap, starting from the SMDCs. (C) Therapeutic activity of the 
different treatments given simultaneously, without time gap between the two injections. 
In both cases, the combination of the AAZ
+
-ValCit-MMAE with L19-IL2 exhibited a su-
perior anti-tumor activity when compared with vehicle and with the combination of 
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AAZ-ValCit-MMAE with L19-IL2. (D) Tolerability of the different treatments as as-
sessed by the evaluation of changes (%) in body weight during the experiment when the 
two treatments were given simultaneously. All treatments were well tolerated and did not 
have an impact on the body weight of the animals. **** indicates p<0.0001; ** indicates 
p<0.01; * indicates p<0.05; ns indicates p>0.05 (2-way ANOVA test, followed by Bon-
ferroni post-test). (E) Therapeutic activity of AAZ
+
-ValCit-MMAE, L19-IL2 as single
agents or in combination as assessed by measurement of tumor volume (mm
3
) during
therapy experiment. Therapy experiment started when the average tumor volume was 
about 200 mm
3
. Data points represent mean tumor volume ± SEM (n = 4 per group). The
two treatments were administered intravenously as bolus injections with a 24-hour gap, 
starting from the SMDCs. (F) Tolerability of the different treatments as assessed by the 
evaluation of changes (%) in body weight during the experiment. **** indicates 
p<0.0001; ** indicates p<0.01; * indicates p<0.05; ns indicates p>0.05 (2-way ANOVA 
test, followed by Bonferroni post-test).  
Figure 3: In vivo efficacy of AAZ-ValCit-MMAE and AAZ
+
-ValCit-MMAE in com-
bination with Anti-PD-1 in immunocompetent BALB/c mice bearing established 
subcutaneous CT26.3E10 colorectal cell carcinoma. (A) Therapeutic activity of the 
different treatments as assessed by measurement of tumor volume (mm
3
) during therapy
experiment. Data points represent mean tumor volume ± SEM (n = 3 per group). The two 
treatments were administered intravenously as bolus injections with a 6 hours window, 
starting from the SMDCs. The combination of the SMDCs with anti-PD-1 exhibited a 
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superior anti-tumor activity when compared with vehicle, AAZ-ValCit-MMAE, AAZ
+
-
ValCit-MMAE or anti-PD-1 only. (B) Tolerability of the different treatments as assessed 
by the evaluation of changes (%) in body weight during the experiment. All treatments 
were well tolerated and did not have an impact on the body weight of the animals. **** 
indicates p<0.0001; ** indicates p<0.01; * indicates p<0.05; ns indicates p>0.05 (2-way 
ANOVA test, followed by Bonferroni post-test). 
Figure 4: In vivo efficacy of AAZ
+
-ValCit-MMAE in combination with L19-IL12 in
BALB/c immunodeficient nu/nu mice bearing established subcutaneous SKRC-52 
renal cell carcinoma with different initial tumor burden (A) Therapeutic activity of 
the different treatments as assessed by measurement of tumor volume (mm
3
) during ther-
apy experiment. Therapy experiment started when the average tumor volume was about 
100 mm
3
. Data points represent mean tumor volume ± SEM (n = 5 per group). The two
treatments were administered intravenously as bolus injections with a 24-hour gap, start-
ing from the SMDCs. The combination of AAZ
+
-ValCit-MMAE with L19-IL12 exhibit-
ed a superior anti-tumor activity when compared with vehicle, L19-IL12 or AAZ
+
-
ValCit-MMAE only. (B) Tolerability of the different treatments as assessed by the evalu-
ation of changes (%) in body weight during the experiment. All treatments were well tol-
erated and did not have an impact on the body weight of the animals. **** indicates 
p<0.0001; ** indicates p<0.01; * indicates p<0.05; ns indicates p>0.05 (2-way ANOVA 
test, followed by Bonferroni post-test). (C) Therapeutic activity of AAZ
+
-ValCit-MMAE,
L19-IL12 as single agents or in combination as assessed by measurement of tumor vol-
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) during therapy experiment. Therapy experiment started when the average tu-
mor volume was about 200 mm
3
. Data points represent mean tumor volume ± SEM (n =
4 per group). The two treatments were administered intravenously as bolus injections 
with a 24-hour gap, starting from the SMDCs. (D) Tolerability of the different treatments 
as assessed by the evaluation of changes (%) in body weight during the experiment. **** 
indicates p<0.0001; ** indicates p<0.01; * indicates p<0.05; ns indicates p>0.05 (2-way 
ANOVA test, followed by Bonferroni post-test).  
Figure 5: Ex vivo histological analysis and plasma analysis after therapy in BALB/c 
immunodeficient nu/nu mice treated with AAZ-ValCit-MMAE or AAZ
+
-ValCit-
MMAE in combination with L19-IL2. (A) Representative pictures of H&E staining on 
kidney, stomach, lung and liver samples from different treated groups of mice collected 
three months after first exposure to the drugs (black scale bar = 100 µm, B = bile ducts in 
the liver, G = glomeruli structures in the kidney, arrow = inflammatory infiltrate with in-
crease of fibrous tissue). (B) Creatinine and (C) urea plasma concentration measured 
three months after treatment with SMDC products, L19-IL2 and combinations of the 
drugs (n = 3 per group). Administration of SMDCs and immunocytokines did not inter-
fere with normal kidney function as demonstrated by physiological levels of creatinine 
and urea in plasma. 
Figure 6: Ex vivo histological analysis after therapy in BALB/c immunodeficient 
nu/nu mice treated with AAZ
+
-ValCit-MMAE in combination with L19-IL12 or
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with L19-IL12 alone. Representative pictures of H&E staining on kidney, stomach, lung 
and liver samples from different treated groups of mice collected three months after first 
exposure to the drugs (black scale bar = 100 µm, B = bile ducts in the liver, G = glomeru-
li structures in the kidney, arrow = inflammatory infiltrate with increase of fibrous tis-
sue). 
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